Product Information for the User
Tapimio 100 mg Extended-Release Tablets EFG
Tapentadol
Read this entire leaflet carefully before you start taking this medicine, as it contains important information for you.
1.What Tapimio is and what it is used for
2.What you need to know before taking Tapimio
3.How to take Tapimio
4.Possible side effects
5.Storage of Tapimio
6.Contents of the pack and additional information
Tapentadol - the active ingredient in Tapimio - is a potent analgesic that belongs to the class of opioids.
Tapimio is used for the treatment of severe chronic pain in adults, which can only be adequately treated with an opioid analgesic.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication:
This medication contains tapentadol, which is an opioid medication. Repeated use of opioid analgesics may reduce the effectiveness of the medication (you may become accustomed to it). It may also lead to dependence and abuse, which may result in a potentially fatal overdose. It is essential to inform your doctor if you think you may have developed dependence on this medication. Your use (even at therapeutic doses) may cause physical dependence, which may lead to withdrawal symptoms and a recurrence of your problems if you stop taking this medication abruptly.
Tapentadol may produce physical and psychological addiction. If you have a tendency to abuse medications or have medication dependence, you should take these tablets only for short periods of time under strict medical supervision.
Respiratory disorders related to sleep
Tapentadol may cause sleep-related respiratory disorders such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nocturnal awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime somnolence. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.
Other medications and Tapimio
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
However, if your doctor prescribes tapentadol with sedatives, you should limit the dose and duration of concomitant treatment.
The concomitant use of opioids and medications used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and may be potentially fatal.
Inform your doctor if you are taking gabapentin or pregabalin or any other sedative, and follow your doctor's dosage recommendations exactly.
It may be helpful to inform friends or family members about the symptoms mentioned above. Contact your doctor when you experience these symptoms.
Taking Tapimio with food, drinks, and alcohol
Do not consume alcohol while taking this medication, as some of its adverse effects, such as drowsiness, may increase. Food intake does not affect the effect of this medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not take this medication:
The use of tapentadol is not recommended:
Driving and operating machinery
This medication may cause drowsiness, dizziness, and blurred vision and may affect your reactions.
This may occur especially when you start taking tapentadol, when your doctor changes your dose, or when you drink alcohol or take tranquilizers. Ask your doctor if you can drive or operate machinery.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Your doctor will adjust the dose based on the intensity of your pain and your personal sensitivity to pain. Generally, you should take the minimum effective dose to relieve pain.
Adults
The recommended starting dose is 50 mg taken twice a day, approximately every 12 hours. Do not recommend daily total doses exceeding 500 mg of tapentadol.
Your doctor may prescribe a different dose or a more suitable dosing regimen if necessary. If you think the effect of these tablets is too strong or too weak, consult your doctor or pharmacist.
Older patients
In older patients (over 65 years old), it is usually not necessary to adjust the dose. However, the elimination of tapentadol may be delayed and slower in certain patients in this age group. If this happens to you, your doctor may prescribe a different dosing regimen.
Liver and kidney diseases (hepatic and renal insufficiency)
Patients with severe liver problems should not take these tablets. If you have moderate liver problems, your doctor will prescribe a different dosing regimen. In the case of mild liver problems, no dose adjustment is necessary.
Patients with severe kidney problems should not take these tablets. In the case of mild or moderate kidney problems, no dose adjustment is necessary.
Use in children and adolescents
Tapentadol is not indicated in children and adolescents under 18 years of age.
How and when to take Tapentadol
Tapentadol should be taken orally.
Always swallow the tablet with sufficient liquid. Do not chew or crush it, as this could lead to an overdose, as the active ingredient will be released in your body too quickly.
You can take the tablets with an empty stomach or with meals.
The tablet can be divided into equal doses.
The coating of the tablet may not be fully digested and may appear, apparently unchanged, in the feces. This should not worry you, as the active ingredient of the tablet will have already been absorbed by the body, and what you see is only the empty coating.
Instructions for opening the blister pack
This medication is packaged in perforated, child-resistant blister packs.
You cannot push the tablets through the blister pack. Please follow the following instructions for opening the blister pack:
2.This will allow access to an uncovered area located at the point where the perforation lines intersect.
For how long should Tapentadol be taken
Do not take the tablets for longer than your doctor has indicated.
If you take more Tapentadol than you should
After taking very high doses, you may experience some of the following effects:
If you experience any of these effects, you should call your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you forget to take Tapimio
If you forget to take a tablet, it is likely that you will feel pain again. Do not take a double dose to compensate for the missed doses, but continue taking the tablets as before.
If you interrupt treatment with Tapimio
If you interrupt or stop treatment too soon, it is likely that you will feel pain again. If you want to interrupt treatment, consult your doctor before doing so.
Generally, patients do not experience any adverse effects after interrupting treatment, but in rare cases, people who have taken the tablets for a long time may feel unwell if they stop taking them suddenly.
The symptoms may be:
If you experience any of these symptoms after interrupting treatment, consult your doctor.
You should not stop taking this medication abruptly, unless your doctor tells you to do so. If your doctor wants you to stop taking these tablets, they will indicate how to do it, which may involve a gradual reduction in dose.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Important side effects or symptoms to be aware of and what to do if you are affected by them:
If you experience any of these important symptoms, consult your doctor immediately.
Side effects that may occur:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Unknown frequency(frequency cannot be estimated with available data)
In general, the possibility of having suicidal thoughts and behaviors increases in patients with chronic pain. Additionally, some medications for treating depression (affecting neurotransmitters in the brain) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, through experience in patients, it has not been proven to increase this risk.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be thrown down the drain or in the trash.Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy.If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
The active principle is tapentadol.
Each prolonged-release tablet contains tapentadol phosphate equivalent to 100 mg of tapentadol.
The other components are:
Tablet core: microcrystalline cellulose (E460); hypromellose (E464); anhydrous colloidal silica (E551); magnesium stearate.
Tablet coating: hypromellose (E464); glycerol (E422); talc (E553b); microcrystalline cellulose (E460); titanium dioxide (E 171); iron oxide red (E172); iron oxide yellow (E172); iron oxide black (E172).
Appearance of the product and contents of the package
Prolonged-release tablets, biconvex, oblong, yellowish (7 mm x 14 mm), with a groove on both faces.
The tablet can be divided into equal doses.
Tapimio 100 mg is packaged in a pre-cut single-dose blister, child-resistant, in packages of 20, 24, 30, 50, 54, 60, or 100 prolonged-release tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Responsible manufacturer:
Develco Pharma GmbH
Grienmatt 27
79650 Schopfheim
Germany
Neuraxpharm Arzneimittel GmgH
Elisabeth-Serbert-Strasse 23
40764 Langenfeld
Germany
This medicine is authorized in the member states of the European Economic Area with the following names:
GermanyTapentadol neuraxpharm 100 mg Retardtabletten
IrelandTapimio 100 mg prolonged-release tablets
SpainTapimio 100 mg prolonged-release tablets EFG
SwedenTapimio Depot 100 mg depot tablets
Last review date of this leaflet: September 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.